Inmatics Biotechnologies, a 3i-backed German bio-pharmaceutical company, has completed a second financing round of €40 million, the largest the country has seen in the sector since 2001.
New investors include US private investment bank DH Capital and German development bank KfW.
The firm had previously completed one of the largest first financing rounds on record for a German biotech company, raising €14 million from investors including global private equity group 3i and German venture firm Wellington Partners.
Dr Harpeet Singh, chief scientific officer and co-founder, said: “This new funding will not only enable us to pursue two parallel Phase II clinical studies on our two most highly developed product candidates, but will also allow us to further expand our pipeline.”
Inmatics, which was founded in 2000 as a spin-off from the Institute of Immunology at the University of Tuebingen, develops new immunotherapeutic substances for cancer therapy.